NEW EQUILIBRIUM BIOSCIENCES, INC.

Cambridge, MA · Founded 2019 · CIK 0001798619 · Biotech · Defunct

Computational-experimental platform using AI-driven molecular dynamics algorithms and NMR screening to discover therapeutics targeting intrinsically disordered proteins

Grants
$256K
1 award
Sector median: 1
Raised
$10M
2 Form D · Apr 2022
53 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Structure-based drug discovery for intrinsically disordered proteins$255,872
Private capital raisedForm D · SEC$249,998
Private capital raisedForm D · SEC$9,999,995
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2355DeepCyte Inc.—$1.4M
2356Unnatural Products Inc.—$23M
2357CELLULAR LOGISTICS, INC.—$1.0M
2358NEW EQUILIBRIUM BIOSCIENCES, INC.—$10M
2359Metalytics, LLC——
2360OLIGOMERIX INC—$2.9M
2361Allinaire Therapeutics, LLC—$950K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 1 related persons
  • Virginia BurgerDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.